Author

Andrea Chassot Agostinho

Observed names: A Chassot-Agostinho, A. Chassot Agostinho, A.C. Agostinho, Agostinho, A. Chassot, Andrea C. Agostinho, Andrea Chassot-Agostinho, Chassot-Agostinho, Andrea

Institutions: Novartis (France), Novartis (United States)

Observed institutions: Novartis (Switzerland), Bayer (United States), Novartis (France), Novartis (United States)

OpenAlex ID: A5047771665

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy

2021 · Jochen Buechner, Stephan A. Grupp, et al. · Blood Advances · 61

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

2021 · Birgit Geoerger, Bruce Morland, et al. · European Journal of Cancer · 29

PDF

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

2021 · Karen Thudium Mueller, Stephan A. Grupp, et al. · Blood Advances · 27

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

2021 · Juergen Wolf, Edward B. Garon, et al. · Journal of Clinical Oncology · 25

Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia

2019 · Hidefumi Hiramatsu, Souichi Adachi, et al. · International Journal of Hematology · 17

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study

2022 · Jürgen Wolf, Edward B. Garon, et al. · European Journal of Cancer · 13

Capmatinib in MET exon 14-mutated advanced NSCLC: updated results from the GEOMETRY mono-1 study.

2022 · J Wolf, E B Garon, et al. · Pneumologie · 10

Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia

2020 · Qiufei Ma, Jie Zhang, et al. · Journal of Comparative Effectiveness Research · 8

Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.

2021 · Yi-Long Wu, Li Zhang, et al. · Journal of Clinical Oncology · 5

Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.

2016 · Birgit Geoerger, Bruce Morland, et al. · Journal of Clinical Oncology · 5

1256P Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial

2021 · R.S. Heist, E.B. Garon, et al. · Annals of Oncology · 4

PDF

Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.

2021 · Rebecca Suk Heist, Edward B. Garon, et al. · Journal of Clinical Oncology · 3

P47.17 Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)

2021 · P. Souquet, S. Kim, et al. · Journal of Thoracic Oncology · 2

PDF

Abstract LB056: Accurate detection of MET exon 14 skipping using a liquid biopsy assay in NSCLC patients in the GEOMETRY mono-1 study

2021 · Rebecca S. Heist, Edward B. Garon, et al. · Cancer Research · 2

P85.04 Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis

2021 · J. Han, J. Wolf, et al. · Journal of Thoracic Oncology · 2

PDF

S1618 Tisagenlecleucel Appears Effective and Safe in Pediatric and Young Adult Patients With Relapsed/refractory Acute Lymphoblastic Leukemia With High‐risk Cytogenetic Abnormalities

2019 · S. Grupp, S. Maude, et al. · HemaSphere · 2

Evaluation of exposure of regorafenib (REG) and its metabolites in pediatric patients by modeling, simulation, and clinical study

2016 · B. Ploeger, J. Grevel, et al. · Annals of Oncology · 2

PDF

1362TiP Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study

2021 · P-J. Souquet, S-W. Kim, et al. · Annals of Oncology

101P The landscape of MET alterations in European cancer patients

2021 · J. Wolf, L-A. Ventouras, et al. · Annals of Oncology

Accurate detection of MET exon 14 skipping using a liquid biopsy assay in NSCLC patients in the GEOMETRY mono-1 study.

2021 · Rebecca S. Heist, Edward B. Garon, et al. · University of Groningen research database (University of Groningen / Centre for Information Technology)

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.

2021 · Juergen Wolf, Edward B. Garon, et al. · Journal of Clinical Oncology

Works count: 24

Citation count: 216

H-index: 8

I10-index: 7